These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32037922)

  • 1. How to manage iron toxicity in post-allogeneic hematopoietic stem cell transplantation?
    Kontoghiorghes GJ
    Expert Rev Hematol; 2020 Apr; 13(4):299-302. PubMed ID: 32037922
    [No Abstract]   [Full Text] [Related]  

  • 2. One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation.
    Inati A; Kahale M; Sbeiti N; Cappellini MD; Taher AT; Koussa S; Nasr TA; Musallam KM; Abbas HA; Porter JB
    Pediatr Blood Cancer; 2017 Jan; 64(1):188-196. PubMed ID: 27576370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors.
    Majhail NS; Lazarus HM; Burns LJ
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):832-7. PubMed ID: 20079863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron overload and allogeneic hematopoietic stem-cell transplantation.
    Kanda J; Kawabata H; Chao NJ
    Expert Rev Hematol; 2011 Feb; 4(1):71-80. PubMed ID: 21322780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of iron overload before, during, and after hematopoietic stem cell transplantation for thalassemia major.
    Angelucci E; Pilo F
    Ann N Y Acad Sci; 2016 Mar; 1368(1):115-21. PubMed ID: 26999450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective cohort study of the feasibility and efficacy of iron reduction by phlebotomy in recipients of hematopoietic SCT.
    Kew AK; Clarke S; Ridler A; Burrell S; Edwards JA; Doucette S; Couban S
    Bone Marrow Transplant; 2015 Mar; 50(3):457-8. PubMed ID: 25501351
    [No Abstract]   [Full Text] [Related]  

  • 7. Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy.
    Busca A; Falda M; Manzini P; D'Antico S; Valfrè A; Locatelli F; Calabrese R; Chiappella A; D'Ardia S; Longo F; Piga A
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):115-22. PubMed ID: 19766730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Assessment and management of post-transplant iron overload: Guidelines of the Francophone Society of Marrow Transplantation and Cellular Therapy (SFGM-TC)].
    Jaspers A; Bouhya S; Belaiche S; Chevallier P; Hermet E; Hospital-Gustems C; Michallet M; Rialland F; Samsonova O; Sirvent A; Yakoub-Agha I; Rohrlich PS; Beguin Y
    Bull Cancer; 2016 Nov; 103(11S):S255-S266. PubMed ID: 27842863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron overload in hematopoietic cell transplantation.
    Majhail NS; Lazarus HM; Burns LJ
    Bone Marrow Transplant; 2008 Jun; 41(12):997-1003. PubMed ID: 18438425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT).
    Sivgin S; Eser B; Bahcebasi S; Kaynar L; Kurnaz F; Uzer E; Pala C; Deniz K; Ozturk A; Cetin M; Unal A
    Ann Hematol; 2012 May; 91(5):743-749. PubMed ID: 22051904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes.
    Ricchi P; Marsella M
    Drug Des Devel Ther; 2015; 9():6475-82. PubMed ID: 26719673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II, Multicenter, Single-Arm Study to Evaluate the Safety and Efficacy of Deferasirox after Hematopoietic Stem Cell Transplantation in Children with β-Thalassemia Major.
    Yesilipek MA; Karasu G; Kaya Z; Kuskonmaz BB; Uygun V; Dag I; Ozudogru O; Ertem M
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):613-618. PubMed ID: 29155313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between Plasma Endothelin-1, Transforming Growth Factor-β, Fibroblast Growth Factor, and Nitric Oxide Levels and Liver Injury in Hematopoietic Stem Cell Transplantation Recipients with Persistent Iron Overload after Transplantation.
    Akı ŞZ; Suyanı E; Cengiz M; Özenirler S; Elbeğ Ş; Paşaoğlu H; Sucak GT
    Biol Blood Marrow Transplant; 2015 May; 21(5):948-53. PubMed ID: 25681034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron depletion by phlebotomy with recombinant erythropoietin prior to allogeneic transplantation to prevent liver toxicity.
    de la Serna J; Bornstein R; García-Bueno MJ; Lahuerta-Palacios JJ
    Bone Marrow Transplant; 1999 Jan; 23(1):95-7. PubMed ID: 10037058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron mobilization using chelation and phlebotomy.
    Flaten TP; Aaseth J; Andersen O; Kontoghiorghes GJ
    J Trace Elem Med Biol; 2012 Jun; 26(2-3):127-30. PubMed ID: 22565013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Kamble RT; Selby GB; Mims M; Kharfan-Dabaja MA; Ozer H; George JN
    Biol Blood Marrow Transplant; 2006 May; 12(5):506-10. PubMed ID: 16635785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron toxicity in hematopoietic stem cell transplantation: Strike while the iron is labile.
    Pullarkat V
    Acta Haematol; 2014; 131(4):220-1. PubMed ID: 24335205
    [No Abstract]   [Full Text] [Related]  

  • 18. The management of iron overload in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients: where do we stand?
    Sivgin S; Eser B
    Ann Hematol; 2013 May; 92(5):577-86. PubMed ID: 23430087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of iron in patients after bone marrow transplantation.
    de Witte T
    Blood Rev; 2008 Dec; 22 Suppl 2():S22-8. PubMed ID: 19059053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302).
    Tachibana T; Kanda J; Machida S; Saito T; Tanaka M; Najima Y; Koyama S; Miyazaki T; Yamamoto E; Takeuchi M; Morita S; Kanda Y; Kanamori H; Okamoto S;
    Int J Hematol; 2018 May; 107(5):578-585. PubMed ID: 29305770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.